Biogen and Eisai release new Alzheimer’s drug data that may support wider uptake
October 25, 2023 at 17:28 PM EDT
Eisai plans to apply for FDA approval of subcutaneous Leqembi by early next year.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions. |
|